RayKnowChina Research Map
Shortlist0

RecruitingMultiple myelomaPhase 1/Phase 2

Registered title, quoted from ClinicalTrials.gov

Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

An open trial on multiple myeloma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 3 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 3

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteBeijing Chao-Yang Hospital首都医科大学附属北京朝阳医院BeijingHospital page
  2. Study siteFirst Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page
  3. Study sitePeking University Third Hospital北京大学第三医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05565807, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Previously treated with at least three drugs (including PI, IMiD, and anti-CD38 antibody), and relapsed/refractory after the most recent anti-MM therapy.

    Inclusion criterion 2

    Women of childbearing potential (WOCBP) (infertile women are defined as sexually mature females who had undergone a hysterectomy or bilateral oophorectomy or bilateral salpingectomy or bilateral tubal ligation/closure, or who are infertile due to a congenital or acquired condition or spontaneously menopausal for ≥ 12 months) must have a negative blood pregnancy test during the screening. Female subjects of childbearing potential and male subjects with fertility must use a highly effective method of contraception from screening to 6 months after the last treatment.

    Inclusion criterion 9

    Had received plasma exchange therapy within 28 days before the first administration of the study drug.

    Exclusion criterion 8

    Had received the following anti-tumor treatments before the first administration of the study drug: monoclonal antibody or cytotoxic drug or radiotherapy within 28 days; immunoregulator, targeted therapy or epigenetic therapy or investigational medical product or invasive investigational medical device or other anti-myeloma therapy within 28 days or 5 half-lives (whichever is shorter); proteasome inhibitor or anti-tumor traditional Chinese medicine treatment or corticosteroids with a cumulative dose of more than 140 mg prednisone (or equivalent) or a single dose of more than 40 mg/day dexamethasone (or equivalent) within 14 days.

    Exclusion criterion 9

    Had received CAR-T therapy or allogeneic hematopoietic stem cell transplantation therapy within 6 months before the first administration of the study drug, or have a concomitant disease of active graft-versus-host disease (GvHD) at screening.

    Exclusion criterion 10

    Had received autologous hematopoietic stem cell transplantation within 12 weeks before the first administration of the study drug.

    Exclusion criterion 11

    The toxicity caused by the previous anti-tumor treatment did not subside to ≤ grade 1.

    Exclusion criterion 16

  3. ECOG performance status score is 0, 1, or 2.

    Inclusion criterion 7

  4. Hemoglobin <80g/L

    Exclusion criterion 18

    Platelet count <50×10\^9/L

    Exclusion criterion 19

    Absolute neutrophil count <1.0×10\^9/L

    Exclusion criterion 20

    Estimated creatinine clearance <30mL/min.

    Exclusion criterion 22

    AST or ALT>3×upper limit of normal (ULN) or serum total bilirubin> 1.5×ULN.

    Exclusion criterion 23

  5. Diagnosis of MM according to IMWG criteria with measurable lesions, meeting at least 1 of the following criteria:

    Inclusion criterion 3

  6. Other malignant diseases within 3 years before the first administration of the study drug.

    Exclusion criterion 13

  7. Is currently pregnant or breast feeding.

    Exclusion criterion 39

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05565807, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age ≥18 years old, regardless of gender.
  • Previously treated with at least three drugs (including PI, IMiD, and anti-CD38 antibody), and relapsed/refractory after the most recent anti-MM therapy.
  • Diagnosis of MM according to IMWG criteria with measurable lesions, meeting at least 1 of the following criteria:
  • Serum M protein ≥ 0.5g/dL (≥ 5 g/L); or
  • Urine M protein ≥ 200mg/24 hours; or
  • When the serum free light chain (FLC) ratio is abnormal, the affected FLC level is ≥10mg/dL (≥100 mg/L) (the normal FLC ratio is 0.26 to 1.65).
  • ECOG performance status score is 0, 1, or 2.
  • Willing and able to comply with the study schedule and all other study protocol requirements.
  • Women of childbearing potential (WOCBP) (infertile women are defined as sexually mature females who had undergone a hysterectomy or bilateral oophorectomy or bilateral salpingectomy or bilateral tubal ligation/closure, or who are infertile due to a congenital or acquired condition or spontaneously menopausal for ≥ 12 months) must have a negative blood pregnancy test during the screening. Female subjects of childbearing potential and male subjects with fertility must use a highly effective method of contraception from screening to 6 months after the last treatment.

Exclusion Criteria:

  • Known hypersensitivity to any of the ingredients of this product.
  • Diagnosis of active plasma cell leukemia.
  • Diagnosis of systemic light chain amyloidosis.
  • MM involving the central nervous system.
  • Has POEMS syndrome.
  • There is spinal cord compression associated with MM.
  • Needs to take concomitant drugs with a strong inhibitory effect or a strong induction effect on CYP3A4.
  • Had received plasma exchange therapy within 28 days before the first administration of the study drug.
  • Had received the following anti-tumor treatments before the first administration of the study drug: monoclonal antibody or cytotoxic drug or radiotherapy within 28 days; immunoregulator, targeted therapy or epigenetic therapy or investigational medical product or invasive investigational medical device or other anti-myeloma therapy within 28 days or 5 half-lives (whichever is shorter); proteasome inhibitor or anti-tumor traditional Chinese medicine treatment or corticosteroids with a cumulative dose of more than 140 mg prednisone (or equivalent) or a single dose of more than 40 mg/day dexamethasone (or equivalent) within 14 days.
  • Had received CAR-T therapy or allogeneic hematopoietic stem cell transplantation therapy within 6 months before the first administration of the study drug, or have a concomitant disease of active graft-versus-host disease (GvHD) at screening.
  • Had received autologous hematopoietic stem cell transplantation within 12 weeks before the first administration of the study drug.
  • Had undergone major surgery or eye surgery within 28 days before the first administration of the study drug.
  • Other malignant diseases within 3 years before the first administration of the study drug.
  • History of grade ≥3 (muscle paralysis, eyelid disease, glaucoma requiring drug control, tearing eyes), or grade ≥2 any other ocular disease (as judged by NCI-CTCAE version 5.0) at screening.
  • Has ≥ Grade 3 neuropathy or Grade 2 neuropathy with associated pain.
  • The toxicity caused by the previous anti-tumor treatment did not subside to ≤ grade 1.
  • Has the following hematological test results within 7 days before the first administration of the study drug:
  • Hemoglobin <80g/L
  • Platelet count <50×10\^9/L
  • Absolute neutrophil count <1.0×10\^9/L
  • Has the following blood chemistry test results within 7 days before the first administration of the study drug:
  • Estimated creatinine clearance <30mL/min.
  • AST or ALT>3×upper limit of normal (ULN) or serum total bilirubin> 1.5×ULN.
  • Severe or uncontrolled cardiovascular and cerebrovascular diseases requiring treatment, including:
  • New York Heart Association class>2;
  • Unstable angina pectoris that cannot be controlled by drugs;
  • Myocardial infarction occurred within 6 months before the first administration of the study drug;
  • Poorly controlled arrhythmias;
  • 12-lead ECG QTcF>470msec;
  • Left ventricular ejection fraction <40%;
  • Poorly controlled hypertension ;
  • Stroke, cerebrovascular accident, or transient ischemic attack occurred within 6 months before the first administration of the study drug.
  • Meets any of the following criteria:
  • Known chronic obstructive pulmonary disease (COPD) and forced expiratory volume in 1 second (FEV1) <50% of predicted normal;
  • Known moderate or severe persistent asthma, or a history of asthma within the past 2 years, or current uncontrolled asthma of any classification;
  • with interstitial lung disease requiring corticosteroid therapy, drug-induced interstitial lung disease, a history of radiation pneumonitis, orclinically active interstitial lung disease suggested by any current evidence before the first administration of the study drug.
  • Has an active bacterial, viral, or fungal infection or needs for intravenous antibiotic administration (IV) within 72 hours before the first administration of the study drug.
  • Active or uncontrolled HBV , HCV , HIV positive.
  • Is currently pregnant or breast feeding.
  • Has any active severe mental illness, medical illness, or other symptoms/conditions that may affect treatment, compliance, or the ability to provide informed consent, as determined by the investigator.

Quoted from ClinicalTrials.gov, NCT05565807, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05565807, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05565807